Pharmaceutical
Engineering
Chemicals

Cambrex

$38.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (0.34%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Cambrex and other stocks, options, ETFs, and crypto commission-free!

About

Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Read More Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.

Employees
1,732
Headquarters
East Rutherford, New Jersey
Founded
1981
Market Cap
1.29B
Price-Earnings Ratio
13.98
Dividend Yield
0.00
Average Volume
388.37K
High Today
$38.53
Low Today
$37.56
Open Price
$38.06
Volume
39.38K
52 Week High
$69.43
52 Week Low
$33.80

Collections

Pharmaceutical
Engineering
Chemicals
Therapy
Health
US
North America

News

TradingNewsNowMar 21

Latest Valuation: Cambrex Corporation (NYSE: CBM)

Cambrex Corporation is part of the biotechnology industry and is in the healthcare sector. The company CEO is Steven M. Klosk. Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. Previous Intraday Trading Performance: The CBM stock showed a previous change of -1.05% with an open at 39.00 and a close of 38.60. It rea...

30
Markets InsiderMar 14

Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan

EAST RUTHERFORD, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy.

53
Yahoo FinanceMar 13

Do You Like Cambrex Corporation (NYSE:CBM) At This P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We’ll look at Cambrex Corporation’s (NYSE:CBM) P/E ratio and reflect on what it tells us about the company’s share price. Cambrex has a price to earnings ratio of 14.1, based on the last twelve months. That corresponds to an earnings yield of approximately 7.1%. See our latest analysis for Cambrex Scroll to continue with content Ad How Do I Calculate A Price To Earnings Ratio? The formul...

7

Earnings

$0.32
$0.69
$1.07
$1.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.